Shijun Zhang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Shijun Zhang has a total of 77 co-authors. Here are the top co-authors by number of shared publications:
- Lang Li
Department of Biomedical Informatics, College of Medicine, The Ohio State University , Columbus, OH 43210
6 shared publications - Lei Wang
Department of Biomedical Informatics, College of Medicine, The Ohio State University , Columbus, OH 43210
4 shared publications - Aditi Shendre
Department of Biomedical Informatics, College of Medicine The Ohio State University Columbus Ohio USA
3 shared publications Andrew Goodwin
Department of Biomedical Informatics, College of Medicine, The Ohio State University , Columbus, OH 43210
3 shared publications- Chien‐Wei Chiang
Department of Biomedical Informatics, College of Medicine The Ohio State University Columbus Ohio USA
3 shared publications - Sara K. Quinney
Department of Pharmacy Practice Purdue University College of Pharmacy West Lafayette Indiana USA
3 shared publications
Latest Publications
- Open Access
- 23 September 2026
- Published by Oxford University Press (OUP) in Journal of the American Medical Informatics Association
- Vol. 33 (12) , 2253-2266
A co-learning framework for maternal and pediatric pharmacotherapy knowledge gap discovery
Objective: Pregnant and breastfeeding women, along with children, represent populations persistently underrepresented in clinical research, leading to uncertainty in clinical decision-making. This study investigated the landscape of pharmacology research concerning pharmacokinetics (PK), pharmaco-epidemiology (PE), and clinical trials (CT) within maternal and pediatric patient populations. Materials and Methods: A pharmacology research landscape in maternal and pediatric patient populations was analyzed using a novel co-learning framework applied to 38 million PubMed abstracts. It incorporated an evolving annotation guideline for abstract labeling, uncertain sampling, annotation error calibration, and large language model training. The co-learning framework enabled human annotators and language models to iteratively learn from each other, optimizing the classification of PK/PE/CT papers. Analysis was restricted to medications prescribed for maternal and pediatric patients, focusing on publication evidence. Results: Co-learning significantly increased the F1-scores for classifying the CT, PE, and PK abstracts from (0.81, 0.84, 0.73) to (0.96, 0.94, 0.93), respectively. On the external validation set, the F1-score increased from (0.81, 0.60, 0.42) to (0.95, 0.88, 0.91) for CT, PE, and PK, respectively. The models identified 376 231 and 879 936 abstracts relevant to maternal and pediatric patients, respectively. In pregnant or postpartum women, 22%–66% prescribed drugs lacked either PK or PE/CT evidence. Among pediatric patients, 8%–40% prescribed drugs had no or weak PK or PE/CT evidence. Discussion: Co-learning is a more effective approach than active learning in obtaining feedback from human annotators for optimizing the language model. With sufficiently labeled samples, a language model such as BioBERT outperformed large language models. Conclusion: In both maternal and pediatric pharmacology research, the absence of PK evidence was notably more frequent compared to PE and CT. This significant finding calls for more pharmacokinetics studies within pediatric and maternal patient populations.
- 23 September 2026
- Published by Oxford University Press (OUP) in Journal of the American Medical Informatics Association
- Vol. 33 (12) , 2253-2266
Open AccessA co-learning framework for maternal and pediatric pharmacotherapy knowledge gap discovery
Objective: Pregnant and breastfeeding women, along with children, represent populations persistently underrepresented in clinical research, leading to uncertainty in clinical decision-making. This study investigated the landscape of pharmacology research concerning pharmacokinetics (PK), pharmaco-epidemiology (PE), and clinical trials (CT) within maternal and pediatric patient populations. Materials and Methods: A pharmacology research landscape in maternal and pediatric patient populations was analyzed using a novel co-learning framework applied to 38 million PubMed abstracts. It incorporated an evolving annotation guideline for abstract labeling, uncertain sampling, annotation error calibration, and large language model training. The co-learning framework enabled human annotators and language models to iteratively learn from each other, optimizing the classification of PK/PE/CT papers. Analysis was restricted to medications prescribed for maternal and pediatric patients, focusing on publication evidence. Results: Co-learning significantly increased the F1-scores for classifying the CT, PE, and PK abstracts from (0.81, 0.84, 0.73) to (0.96, 0.94, 0.93), respectively. On the external validation set, the F1-score increased from (0.81, 0.60, 0.42) to (0.95, 0.88, 0.91) for CT, PE, and PK, respectively. The models identified 376 231 and 879 936 abstracts relevant to maternal and pediatric patients, respectively. In pregnant or postpartum women, 22%–66% prescribed drugs lacked either PK or PE/CT evidence. Among pediatric patients, 8%–40% prescribed drugs had no or weak PK or PE/CT evidence. Discussion: Co-learning is a more effective approach than active learning in obtaining feedback from human annotators for optimizing the language model. With sufficiently labeled samples, a language model such as BioBERT outperformed large language models. Conclusion: In both maternal and pediatric pharmacology research, the absence of PK evidence was notably more frequent compared to PE and CT. This significant finding calls for more pharmacokinetics studies within pediatric and maternal patient populations.
- Top Cited PapersOpen Access
- 23 February 2026
- Published by Wiley in Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy
- Vol. 46 (3) , e70096
Maternal and Pediatric Precision in Therapeutic Knowledge Portal ( MPRINT ‐ KP ): Landscape Analysis of Pharmacology Research in Maternal and Pediatric Patient Populations
Pregnant women and children have been underrepresented in clinical studies due to ethical concerns and perceived vulnerabilities. This resulted in a significant gap in knowledge regarding the safety and efficacy of medications for these populations. Maternal and Pediatric PRecision In Therapeutics Knowledge Portal (MPRINT‐KP) is designed to provide a comprehensive view of pharmacokinetic, pharmaco‐epidemiology, and clinical trial research evidence in maternal and pediatric patient populations. MPRINT‐KP Silver was generated upon BioBERT models, due to their supreme performance in classifying pharmacokinetic, pharmaco‐epidemiology, and clinical trial papers from PubMed, with an F1‐score > 0.91. As of April 1, 2025, MPRINT‐KP Silver contains 758,560 clinical pharmacology research papers in maternal and pediatric populations. The landscape analysis revealed a large number of drugs with pharmacology knowledge gaps, which is calculated as the relative frequency of drugs with no or weak (i.e., less than five publications) evidence in each of pharmacokinetic, pharmaco‐epidemiology, or clinical trial study type. The highest pharmacotherapy knowledge gaps are in postpartum women, pregnant women, and pediatric patients between 0–12 and 12–18 years of age (51.37%, 32.47%, 25.82%, 32.11%, respectively). Pharmacovigilance analyses were conducted on highly prescribed drugs with limited pharmacology evidence in pediatric patients 0–2 year old and pregnant women using United States Food and Drug Administration Adverse Event Reporting System (FAERS) and MarketScan claims data. A number of new drug‐associated adverse drug events (ADEs) were discovered. In pediatric patients, there were crisaborole‐associated hemorrhage and moxifloxacin‐associated cardiac toxicities. In pregnant women, the analysis revealed terconazole‐associated abnormalities of heartbeat; benzonatate‐associated depressive and anxiety disorders; buspirone‐associated abnormalities of heartbeat; cyclobenzaprine‐associated tubulo‐interstitial nephritis; and pantoprazole‐associated hearing loss and voice and resonance disorders. For the first time, a large‐scale landscape analysis of pharmacotherapy knowledge gap in both maternal and pediatric patient populations was conducted and identified new drug associated ADE evidence using real world data.
- 23 February 2026
- Published by Wiley in Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy
- Vol. 46 (3) , e70096
Top Cited PapersOpen AccessMaternal and Pediatric Precision in Therapeutic Knowledge Portal ( MPRINT ‐ KP ): Landscape Analysis of Pharmacology Research in Maternal and Pediatric Patient Populations
Pregnant women and children have been underrepresented in clinical studies due to ethical concerns and perceived vulnerabilities. This resulted in a significant gap in knowledge regarding the safety and efficacy of medications for these populations. Maternal and Pediatric PRecision In Therapeutics Knowledge Portal (MPRINT‐KP) is designed to provide a comprehensive view of pharmacokinetic, pharmaco‐epidemiology, and clinical trial research evidence in maternal and pediatric patient populations. MPRINT‐KP Silver was generated upon BioBERT models, due to their supreme performance in classifying pharmacokinetic, pharmaco‐epidemiology, and clinical trial papers from PubMed, with an F1‐score > 0.91. As of April 1, 2025, MPRINT‐KP Silver contains 758,560 clinical pharmacology research papers in maternal and pediatric populations. The landscape analysis revealed a large number of drugs with pharmacology knowledge gaps, which is calculated as the relative frequency of drugs with no or weak (i.e., less than five publications) evidence in each of pharmacokinetic, pharmaco‐epidemiology, or clinical trial study type. The highest pharmacotherapy knowledge gaps are in postpartum women, pregnant women, and pediatric patients between 0–12 and 12–18 years of age (51.37%, 32.47%, 25.82%, 32.11%, respectively). Pharmacovigilance analyses were conducted on highly prescribed drugs with limited pharmacology evidence in pediatric patients 0–2 year old and pregnant women using United States Food and Drug Administration Adverse Event Reporting System (FAERS) and MarketScan claims data. A number of new drug‐associated adverse drug events (ADEs) were discovered. In pediatric patients, there were crisaborole‐associated hemorrhage and moxifloxacin‐associated cardiac toxicities. In pregnant women, the analysis revealed terconazole‐associated abnormalities of heartbeat; benzonatate‐associated depressive and anxiety disorders; buspirone‐associated abnormalities of heartbeat; cyclobenzaprine‐associated tubulo‐interstitial nephritis; and pantoprazole‐associated hearing loss and voice and resonance disorders. For the first time, a large‐scale landscape analysis of pharmacotherapy knowledge gap in both maternal and pediatric patient populations was conducted and identified new drug associated ADE evidence using real world data.
- Open Access
- 1 October 2025
- Published by Wiley in Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy
- Vol. 45 (10) , 667-676
Identifying Pediatric Drug Safety Knowledge Gaps: An Integrated Approach Leveraging Real‐World Data, a Biomedical Knowledge Base, and Postmarketing Surveillance Data
Background: Drug safety has historically been understudied in pediatric populations, rendering them “therapeutic orphans.” Pediatric drug indications and dosages are often inferred by extrapolating safety, efficacy, and dosing data from adult studies, leading to widespread off‐label use. However, this approach fails to account for age‐specific differences in disease pathophysiology and developmental pharmacokinetics (PK). Despite evidence that adverse drug events (ADEs) manifest with greater severity in pediatric populations than in adults, fewer than 50% of drugs have been systematically studied for pediatric use. The lack of robust drug safety data may result in suboptimal or harmful treatment strategies.Methods: We used a data‐driven approach that integrated three databases —including Merative MarketScan claims, the Maternal and Pediatric Precision in Therapeutics (MPRINT) Knowledgebase (including 670,185 pediatric pharmacoepidemiology, PK, and clinical trial publications on 5062 drugs), the United States Food and Drug Administration (FDA) Adverse Event Reporting System (FAERS, a postmarketing safety surveillance database), and FDA drug label data— to identify high‐impact target. High‐impact targets were defined as drugs that have a high prescription volume, limited safety evidence and high risk of serious ADEs.Results: With 229,550 prescriptions in MarketScan, only 9 studies, and almost 50 high risk serious ADEs benzonatate was identified as a high‐impact drug of concern. Serious ADEs included seizure, death, and arrhythmia with proportional reportion ratios (PRRs) ranging from 4.3 to 477.8.Conclusion: Approved in 1958, Benzonatate, a nonnarcotic antitussive agent has a limited safety evidence with only nine PE/PK publications in six decades. Moreover, it is frequently prescribed off‐label for cough relief despite questionable effectiveness, and high‐risk of serious ADEs. Our findings reveal a disconnect between clinical practice and suppporting safety evidence. As such, there is critical need to study the safety of this drug using emerging real‐world data for real‐world evidence. In summary, this study presents an approach that is systematic, objective, reproducible, and data driven to identify and prioritize drug‐ADE combinations with limited evidence.
- 1 October 2025
- Published by Wiley in Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy
- Vol. 45 (10) , 667-676
Open AccessIdentifying Pediatric Drug Safety Knowledge Gaps: An Integrated Approach Leveraging Real‐World Data, a Biomedical Knowledge Base, and Postmarketing Surveillance Data
Background: Drug safety has historically been understudied in pediatric populations, rendering them “therapeutic orphans.” Pediatric drug indications and dosages are often inferred by extrapolating safety, efficacy, and dosing data from adult studies, leading to widespread off‐label use. However, this approach fails to account for age‐specific differences in disease pathophysiology and developmental pharmacokinetics (PK). Despite evidence that adverse drug events (ADEs) manifest with greater severity in pediatric populations than in adults, fewer than 50% of drugs have been systematically studied for pediatric use. The lack of robust drug safety data may result in suboptimal or harmful treatment strategies.Methods: We used a data‐driven approach that integrated three databases —including Merative MarketScan claims, the Maternal and Pediatric Precision in Therapeutics (MPRINT) Knowledgebase (including 670,185 pediatric pharmacoepidemiology, PK, and clinical trial publications on 5062 drugs), the United States Food and Drug Administration (FDA) Adverse Event Reporting System (FAERS, a postmarketing safety surveillance database), and FDA drug label data— to identify high‐impact target. High‐impact targets were defined as drugs that have a high prescription volume, limited safety evidence and high risk of serious ADEs.Results: With 229,550 prescriptions in MarketScan, only 9 studies, and almost 50 high risk serious ADEs benzonatate was identified as a high‐impact drug of concern. Serious ADEs included seizure, death, and arrhythmia with proportional reportion ratios (PRRs) ranging from 4.3 to 477.8.Conclusion: Approved in 1958, Benzonatate, a nonnarcotic antitussive agent has a limited safety evidence with only nine PE/PK publications in six decades. Moreover, it is frequently prescribed off‐label for cough relief despite questionable effectiveness, and high‐risk of serious ADEs. Our findings reveal a disconnect between clinical practice and suppporting safety evidence. As such, there is critical need to study the safety of this drug using emerging real‐world data for real‐world evidence. In summary, this study presents an approach that is systematic, objective, reproducible, and data driven to identify and prioritize drug‐ADE combinations with limited evidence.
- Open Access
- 15 May 2025
- Published by Wiley in Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy
- Vol. 45 (6) , 367-385
Pharmacotherapy research landscape and knowledge gaps of opioids in maternal and pediatric populations
The use and misuse of opioids has surged in the past decade, with nearly half of the users being female. Although opioid use is lower among pregnant women, trends mirror the general population. While pediatric exposures largely occur through prescriptions. This review presents a novel landscape analysis of pharmacology knowledge gaps in opioids in the maternal and pediatric populations. We queried PubMed for studies on 27 opioids, focusing on pharmacokinetics (PK), and pharmacoepidemiology (PE) or clinical trials (CT) in maternal and pediatric populations. English‐language publications were included, and data were synthesized to identify gaps. Additionally, MarketScan claims data and United States Food and Drug Administration (FDA) drug labels were analyzed to compare scientific evidence, opioid prescriptions/orders, and FDA recommendations. Morphine, fentanyl, methadone, and buprenorphine are the most researched opioids in PK and PE/CT literature in both populations, but hydrocodone, oxycodone, and codeine are the most prescribed. Nine opioids lack FDA labels, and four of the 18 labeled drugs lack any human data. Hydrocodone, oxycodone, and codeine labels include lactation‐focused PK information, with some pediatric clinical data for the latter two. Seven opioids lack PK and PE/CT studies in the maternal population, and PK research is absent for seven opioids, and PE/CT data is lacking for eight opioids in the pediatric population. PK studies often focus on labor, delivery, and lactation accompanied by neonatal data, whereas pregnancy research mainly occurs in PE studies. In pediatric populations, study types are evenly distributed among children, but PE studies focus more on adolescents. Drug concentration is the most reported parameter in PK studies, and neonatal opioid withdrawal syndrome (NOWS) is a key outcome in both PK and PE studies. NOWS is also researched more using real‐world data, whereas neurodevelopmental outcomes are often captured in prospective observational studies. There is substantial disparity between the most commonly researched and prescribed opioids. In particular, the opioid pharmacology knowledge gaps are larger in pregnant women and for the highly prescribed opioids hydrocodone and oxycodone. The limited human data in FDA labels underscores the need for additional studies. Studies using real‐world data can potentially help address these gaps.
- 15 May 2025
- Published by Wiley in Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy
- Vol. 45 (6) , 367-385
Open AccessPharmacotherapy research landscape and knowledge gaps of opioids in maternal and pediatric populations
The use and misuse of opioids has surged in the past decade, with nearly half of the users being female. Although opioid use is lower among pregnant women, trends mirror the general population. While pediatric exposures largely occur through prescriptions. This review presents a novel landscape analysis of pharmacology knowledge gaps in opioids in the maternal and pediatric populations. We queried PubMed for studies on 27 opioids, focusing on pharmacokinetics (PK), and pharmacoepidemiology (PE) or clinical trials (CT) in maternal and pediatric populations. English‐language publications were included, and data were synthesized to identify gaps. Additionally, MarketScan claims data and United States Food and Drug Administration (FDA) drug labels were analyzed to compare scientific evidence, opioid prescriptions/orders, and FDA recommendations. Morphine, fentanyl, methadone, and buprenorphine are the most researched opioids in PK and PE/CT literature in both populations, but hydrocodone, oxycodone, and codeine are the most prescribed. Nine opioids lack FDA labels, and four of the 18 labeled drugs lack any human data. Hydrocodone, oxycodone, and codeine labels include lactation‐focused PK information, with some pediatric clinical data for the latter two. Seven opioids lack PK and PE/CT studies in the maternal population, and PK research is absent for seven opioids, and PE/CT data is lacking for eight opioids in the pediatric population. PK studies often focus on labor, delivery, and lactation accompanied by neonatal data, whereas pregnancy research mainly occurs in PE studies. In pediatric populations, study types are evenly distributed among children, but PE studies focus more on adolescents. Drug concentration is the most reported parameter in PK studies, and neonatal opioid withdrawal syndrome (NOWS) is a key outcome in both PK and PE studies. NOWS is also researched more using real‐world data, whereas neurodevelopmental outcomes are often captured in prospective observational studies. There is substantial disparity between the most commonly researched and prescribed opioids. In particular, the opioid pharmacology knowledge gaps are larger in pregnant women and for the highly prescribed opioids hydrocodone and oxycodone. The limited human data in FDA labels underscores the need for additional studies. Studies using real‐world data can potentially help address these gaps.
- Open Access
- 18 January 2025
- Published by Oxford University Press (OUP) in Database: The Journal of Biological Databases and Curation
- Vol. 2025
DrugCombo: an informatics bridge for anticancer drug combination Phase I trial design
The promise of combinational drug therapies for cancer is hindered by the high failure rate of Phase I trials, perhaps attributable to the inavailability of an integrated source of toxicity data for cancer drugs to aid clinicians and biostatisticians designing trials. To this end, we developed DrugCombo, a knowledge base that integrates drug toxicity along with other data for single drugs and drug combinations from various sources. We extracted drug toxicity data from drug labels using the Microsoft Research Bidirectional Encoder Representations from Transformers for Biomedical Text Mining (MSR BiomedBERT) and manually from PubMed. DrugCombo is the first such database to contain crucial data, such as maximum tolerable dose (MTD), dose-limiting toxicity (DLT), and dose range, for Phase I clinical trial design as well as pharmacokinetics evidence of drug interaction among cancer drugs. Currently, DrugCombo has integrated 8797 drug interactions from DrugBank; 3995 severe adverse drug events (ADEs) and 95 535 common ADEs from drug labels; 1 816 030 ADEs from United States Food and Drug Administration Adverse Event Reporting System; and MTD and DLTs from 2592 Phase I trials. Using these data, we retrospectively investigated a Phase I trial of axitinib and nivolumab in 12 patients. Exploring the toxicity profile of each drug, we recognized that the initial study design may have overlooked overlap toxicity between them, leading to possibly excessive starting doses and dose ranges of axitinib and nivolumab. DrugCombo provides a comprehensive resource of toxicity data that will assist researchers designing Phase I trials in selecting appropriate starting doses and dose ranges for successful outcomes. Database URL: http://drugcombo.info/
- 18 January 2025
- Published by Oxford University Press (OUP) in Database: The Journal of Biological Databases and Curation
- Vol. 2025
Open AccessDrugCombo: an informatics bridge for anticancer drug combination Phase I trial design
The promise of combinational drug therapies for cancer is hindered by the high failure rate of Phase I trials, perhaps attributable to the inavailability of an integrated source of toxicity data for cancer drugs to aid clinicians and biostatisticians designing trials. To this end, we developed DrugCombo, a knowledge base that integrates drug toxicity along with other data for single drugs and drug combinations from various sources. We extracted drug toxicity data from drug labels using the Microsoft Research Bidirectional Encoder Representations from Transformers for Biomedical Text Mining (MSR BiomedBERT) and manually from PubMed. DrugCombo is the first such database to contain crucial data, such as maximum tolerable dose (MTD), dose-limiting toxicity (DLT), and dose range, for Phase I clinical trial design as well as pharmacokinetics evidence of drug interaction among cancer drugs. Currently, DrugCombo has integrated 8797 drug interactions from DrugBank; 3995 severe adverse drug events (ADEs) and 95 535 common ADEs from drug labels; 1 816 030 ADEs from United States Food and Drug Administration Adverse Event Reporting System; and MTD and DLTs from 2592 Phase I trials. Using these data, we retrospectively investigated a Phase I trial of axitinib and nivolumab in 12 patients. Exploring the toxicity profile of each drug, we recognized that the initial study design may have overlooked overlap toxicity between them, leading to possibly excessive starting doses and dose ranges of axitinib and nivolumab. DrugCombo provides a comprehensive resource of toxicity data that will assist researchers designing Phase I trials in selecting appropriate starting doses and dose ranges for successful outcomes. Database URL: http://drugcombo.info/
- Open Access
- 25 May 2022
- Published by Oxford University Press (OUP) in Database: The Journal of Biological Databases and Curation
- Vol. 2022
Translational drug–interaction corpus
The discovery of drug–drug interactions (DDIs) that have a translational impact among in vitro pharmacokinetics (PK), in vivo PK and clinical outcomes depends largely on the quality of the annotated corpus available for text mining. We have developed a new DDI corpus based on an annotation scheme that builds upon and extends previous ones, where an abstract is fragmented and each fragment is then annotated along eight dimensions, namely, focus, polarity, certainty, evidence, directionality, study type, interaction type and mechanism. The guideline for defining these dimensions has undergone refinement during the annotation process. Our DDI corpus comprises 900 positive DDI abstracts and 750 that are not directly relevant to DDI. The abstracts in corpus are separated into eight categories of DDI or non-DDI evidence: DDI with pharmacokinetic (PK) mechanism, in vivo DDI PK, DDI clinical, drug–nutrition interaction, single drug, not drug related, in vitro pharmacodynamic (PD) and case report. Seven annotators, three annotators with drug–interaction research experience and four annotators with less drug–interaction research experience independently annotated the DDI corpus, where two researchers independently annotated each After two rounds of annotations with additional training in between, agreement improved from (0.79, 0.96, 0.86, 0.70, 0.91, 0.65, 0.78, 0.90) to (0.93, 0.99, 0.96, 0.94, 0.95, 0.93, 0.96, 0.97) for focus, certainty, evidence, study type, interaction type, mechanisms, polarity and direction, respectively. The novice-level annotators improved from 0.83 to 0.96, while the expert-level annotators stayed in high performance with some improvement, from 0.90 to 0.96. In summary, we achieved 96% agreement among each pair of annotators with regard to the eight dimensions. The annotated corpus is now available to the community for inclusion in their text-mining pipelines. Database URLhttps://github.com/zha204/DDI-Corpus-Database/tree/master/DDI%20corpus
- 25 May 2022
- Published by Oxford University Press (OUP) in Database: The Journal of Biological Databases and Curation
- Vol. 2022
Open AccessTranslational drug–interaction corpus
The discovery of drug–drug interactions (DDIs) that have a translational impact among in vitro pharmacokinetics (PK), in vivo PK and clinical outcomes depends largely on the quality of the annotated corpus available for text mining. We have developed a new DDI corpus based on an annotation scheme that builds upon and extends previous ones, where an abstract is fragmented and each fragment is then annotated along eight dimensions, namely, focus, polarity, certainty, evidence, directionality, study type, interaction type and mechanism. The guideline for defining these dimensions has undergone refinement during the annotation process. Our DDI corpus comprises 900 positive DDI abstracts and 750 that are not directly relevant to DDI. The abstracts in corpus are separated into eight categories of DDI or non-DDI evidence: DDI with pharmacokinetic (PK) mechanism, in vivo DDI PK, DDI clinical, drug–nutrition interaction, single drug, not drug related, in vitro pharmacodynamic (PD) and case report. Seven annotators, three annotators with drug–interaction research experience and four annotators with less drug–interaction research experience independently annotated the DDI corpus, where two researchers independently annotated each After two rounds of annotations with additional training in between, agreement improved from (0.79, 0.96, 0.86, 0.70, 0.91, 0.65, 0.78, 0.90) to (0.93, 0.99, 0.96, 0.94, 0.95, 0.93, 0.96, 0.97) for focus, certainty, evidence, study type, interaction type, mechanisms, polarity and direction, respectively. The novice-level annotators improved from 0.83 to 0.96, while the expert-level annotators stayed in high performance with some improvement, from 0.90 to 0.96. In summary, we achieved 96% agreement among each pair of annotators with regard to the eight dimensions. The annotated corpus is now available to the community for inclusion in their text-mining pipelines. Database URLhttps://github.com/zha204/DDI-Corpus-Database/tree/master/DDI%20corpus